Keyword health, best known for its COVID-19 molecular test at home, will launch its own virtual health platform and push the company out of diagnostics.
The direct-to-consumer platform, available November 15, will include on-demand doctor access, guided COVID-19 tests, prescriptions and doctor-ordered laboratory tests. The virtual nursing offers are part of a membership program where customers can pay a monthly fee for a number of tests per year, plus discounts on a cue reader and additional tests.
“I think the differentiator here is that we are leading with an extremely powerful, powerful diagnostic product and have the ability to link that test result to a doctor right away if you want,” Clint Sever, Co-Founder and Chief Product Officer of Cue Health, told MobiHealthNews.
“Or, for whatever reason, you can come on the platform and access our medical suite. You can prescribe for any necessary condition, so there is a lot of flexibility built into the platform, which we think is very important. “
WHY IT IS IMPORTANT
Once again a niche method for healthcare, telemedicine and virtual care exploded during the pandemic as patients and providers avoided unnecessary personal care. Although telemedicine usage had decreased in June and July, FAIR Health’s monthly Telehealth Regional Tracker found that usage increased nationwide in August, particularly in the south, as the Delta variant spread across the region.
And as more people return to travel, group meetings and events, Sever said the monitored COVID-19 testing capabilities offered as part of Cue’s virtual mentoring will also help differentiate its platform.
“A lot of people, especially when they travel, want this lab-quality result,” Sever said. “But they can’t get that lab-quality result unless they go through a really tedious process of showing up at a testing site and waiting 24 to 48 hours for the test results, which may or may not be delivered to them on time. especially if you have a tight schedule. “
THE BIGGER TREND
Cue had a busy year 2021. March received it Emergency approval from the Food and Drug Administration for their diagnostic COVID-19 test, which does not require a prescription and can be used at home. It had received an EUA for a point-of-care test for the first time in June 2020.
The company achieved a strong $ 235 million in new funds in May and announced plans to go public in early September. By the end of the month, the company had launched its $ 200 million initial public offering.
Sever said the company is working to expand diagnostic offerings compatible with the Cue Reader, including testing for flu, respiratory syncytial virus (RSV), chlamydia, gonorrhea, fertility, and pregnancy. But Cue’s long-term plans go beyond diagnosis.
“The aim is always to give everyone access to the health system, from home or wherever they are. To make it extremely easy to bring the health system to you, ”Sever said. “So that the digital transformation of the healthcare system remains our mission. And I think this DTC [direct-to-consumer] Going to market is the first big step to enable this broader vision. “